Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whose the Charles Vaccaro of Kali Inc?
going down on news, unless the insiders want it to go up today!
BEWARE! Kali is a massive scam. Trades like the devil trades it. Good luck.
Kali is a scam. No doubt about it
What a crappy website. They are not selling nothin on it. What a waste of money. They sure spend a lot on worthless pump pr's and websites that drop the stock 20%. You know it's those insiders dropped the hell out of it this morning. I seen POTN trade for a long time. This is shadier than a Charles Vaccaro scam how it trades.
New PR on TD ameritrade.
KALY - Kali Extracts Announces New Website For Its RespRx CBD Formulation To Treat Chronic Obstructive Pulmonary Disease Affecting 65 Million Worldwide
9:00 am ET August 23, 2019 (Globe Newswire) Print
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today published a new website dedicated to providing information on the company's recently introduced CBD Formulation, RespRx, for the treatment of Chronic Obstructive Pulmonary Disease (COPD) affecting 65 million people worldwide. KALY introduced the new CBD Formulation earlier this week after making a patent application and trademark registration for the formulation. The website will be continually updated with information about the patent and application trademark progress and the ongoing RespRx medical trials and developments as the company advances toward FDA approval.
US Patented Cannabis Extraction Process For Development Of Cannabis Therapies
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction process. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
KALY has implemented a long-term sustainable overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company's long-term success. KALY, through partnership and independently, has also introduced to market a number of CBD infused consumer food products and a new CBD extraction service for hemp farming operations.
250% 2019 YTD Revenue Growth
The revenue realized in the first six months of 2019 comes primarily from KALY's various CBD infusion offerings. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company's cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY's new cannabis business has seen the company's revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY also realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
More Dramatic Revenue Growth Anticipated 2 Half Of 2019
Drawing on KALY's patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations.
KALY management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.
Updated KALY Analyst Report Planned For Publication Next Week
In addition to the corporate financial disclosures released yesterday, KALY's alternative reporting site, www.kaly-info.com, includes an analyst report on KALY's overall business operation in addition to other useful information. In conjunction with the recent cannabis extract biopharmaceutical business updates made this week, KALY anticipates publishing an updated analyst report next week.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
Analyst Reports
Search News
Search
Article Tools
Set News Alert
Companies Mentioned
Symbol
Last
Change
KALY
$0.009
-13.46%
Back to News Overview
Press Release: KALY - Kali-Extracts Realizes 250% Revenue Growth From New Cannabis Business With Even More Dramatic Growth Anticipated In Second Half Of 2019
8/22/19 9:01 AM ET (Dow Jones)Print
KALY - Kali-Extracts Realizes 250% Revenue Growth From New Cannabis Business With Even More Dramatic Growth Anticipated In Second Half Of 2019
-- KALY 1st Six Months 2019 Revenue Is $165,000 Compared To $46,000 Last
Year
-- KALY Also Reported $70,000 Operating Net Income 1st Six Months 2019
-- 250% Revenue Growth Results From Q4 2018 Cannabis Business Acquired Q4
2018
-- KALY Owns And Operates Patented Cannabis Extraction Process And Has Filed
For A Second Patent On A New Biopharmaceutical CBD Formulation
-- Hemp Farming CBD Extraction Contracts Anticipated To Result In Even More
Dramatic Revenue Growth In Second Half Of 2019
-- KALY Plans To Publish Website Tomorrow Dedicated To New CBD Formulation
And Corresponding Patent Application
-- KALY Anticipates An Analyst Update To Be Published On The Company Next
Week
DALLAS, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced publishing its up-to-date corporate financials through the end of Q2 2019. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company's cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY's new cannabis business has seen the company's revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY also realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
Earlier this week, KALY announced filing a new patent application specifically on its formulation for symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's existing patented cannabis extraction process. The company has also filed to register a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. KALY plans to publish a website on Friday, August 23(rd) , dedicated to its new CBD formulation, RespRx, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RespRx website to be published Friday will include details on KALY's recent patent and trademark applications for the RespRx CBD formulation.
KALY has implemented a long-term sustainable overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company's long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY's patented extraction process offers arguably the highest quality extract to the infusion market. KALY, through partnership and independently, has also introduced to market a number of CBD infused consumer food products. The revenue realized in the first six months of 2019 comes primarily from KALY's various CBD infusion offerings.
Drawing on KALY's patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations. KALY management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.
KALY management is committed to providing timely disclosures consistent with OTC Markets' Pink Current Information Alternative Reporting Standard. Shortly after executing the acquisition of NCMB and implementing a cannabis business shift, OTC Markets implemented a buyer beware flag urging caution in regard to a KALY investment. KALY management continues to work toward resolving the concerns that resulted in the flag. In the meantime, KALY management has published an alternative disclosure site in order to provide timely disclosures of the most up-to-date corporate information. The up-to-date corporate financial information referenced in this release can be found on the company's alternative disclosure site -- www.kaly-info.com. In addition to the corporate financial disclosures, KALY's alternative reporting site includes an analyst report on KALY's overall business operation in addition to other useful information. In conjunction with the recent cannabis extract biopharmaceutical business updates made this week, KALY anticipates publishing an updated analyst report next week.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
(END) Dow Jones Newswires
August 22, 2019 09:01 ET (13:01 GMT)
good stuff thanx. Looking good.
Tomorrow is here. Where is the site?
Kali Inc KALY:OTC Pink - No Information
KALY - Kali-Extracts Confirm Website Launch For RespRx CBD COPD Treatment Formulation Scheduled For Tomorrow
GlobeNewswire
1:32 PM ET
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today confirmed a scheduled website launch for tomorrow dedicated to the company's recently announced RespRx CBD Formulation for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RespRx website to be published Friday, August 23, 2019, will include details on KALY's recent patent and trademark applications for the RespRx CBD formulation.
US Patented Cannabis Extraction Process For Development Of Cannabis Therapies
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
250% 2019 YTD Revenue Growth
KALY has implemented a long-term sustain able overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company's long-term success. KALY, through partnership and independently, has also introduced to market a number of CBD infused consumer food products.
The revenue realized in the first six months of 2019 comes primarily from KALY's various CBD infusion offerings. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company's cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY's new cannabis business has seen the company's revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY a lso realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
More Dramatic Revenue Growth Anticipated 2 Half Of 2019
Drawing on KALY's patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations. KALY management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.
Updated KALY Analyst Report Planned For Publication Next Week
In addition to the corporate financial disclosures released earlier today, KALY's alternative reporting site, www.kaly-info.com, includes an analyst report on KALY's overall business operation in addition to other useful information. In conjunction with the recent cannabis extract biopharmaceutical business updates made this week, KALY anticipates publishing an updated analyst report next week.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
I just emailed Kali-extracts the website to confirm if this is their site. I will update if they respond. They are releasing a separate website for resp rx cbd copd treatment. Kali inc has different websites, for different products. Pot Network with Diamond CBD and their multiple websites for different type of CBD products. They have Diamond Hemp for lotions and cosmetics, and Diamond CBD for ingestible products. You might be right. I will double check. I don't think I am. But maybe since the products are not 99% THC, maybe your right. That oil does look unreal. Hope your wrong.
via OTC PR WIRE – Kali-Extracts (aka Kali, Inc.) (KALY) (“KALY”) today confirmed the company is partnering with Puration, Inc… ---- So your saying Kali's one of a kind extraction method, "claimed to be better than GW pharmaceutical's" is not this unreal one of a kind oil I am seeing in Kaliextracts.com? That has to be the oil, because Lloyd knows oil and that oil is definitely the sexiest I ever seen. I am smoking on Michigan's finest Oil by Church Cannabis baptism of fire OG kush. The Kali extracts looks superior. The oil I am vaping is fire. That oil by Kali extracts looks like it was made for the gods. Like, "nectar of the gods style." It's the same company. Don't be fooled. We about to run hard if this website is dropped today.
Kali inc website.
You might be right, but I need to make money now, can't wait around.
Will investors who lost money because of this scam see restitution? I lost a good chunk of cash on this B.S. Live and learn. I got to flip hard the next few months to make back my losses.
WOW! The Cannabis oil they sell looks like golden liquid silk. Best looking oil I ever seen. This stock is real, simply because the oil they sell is definitely one of a kind. Truth is, Kaly might be the best cannabis stock to buy if the Oil they sell is as good as it looks. Website today, expecting a big run hopefully. Kaly is real deal, just wait till they start putting out audited fins.
Might have a big end of the day run.
News out. Website for COPD CBD treatment comes online tomorrow!
This is just getting started. We hit bottom IMO
Website out for COPD treatment tomorrow! I have COPD so I definitely will order! BusinessWire, GlobeNewswire and PR Newswire News
Kali Inc KALY:OTC Pink - No Information
KALY - Kali-Extracts Confirm Website Launch For RespRx CBD COPD Treatment Formulation Scheduled For Tomorrow
GlobeNewswire
1:32 PM ET
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today confirmed a scheduled website launch for tomorrow dedicated to the company's recently announced RespRx CBD Formulation for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RespRx website to be published Friday, August 23, 2019, will include details on KALY's recent patent and trademark applications for the RespRx CBD formulation.
US Patented Cannabis Extraction Process For Development Of Cannabis Therapies
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
250% 2019 YTD Revenue Growth
KALY has implemented a long-term sustain able overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company's long-term success. KALY, through partnership and independently, has also introduced to market a number of CBD infused consumer food products.
The revenue realized in the first six months of 2019 comes primarily from KALY's various CBD infusion offerings. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company's cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY's new cannabis business has seen the company's revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY a lso realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
More Dramatic Revenue Growth Anticipated 2 Half Of 2019
Drawing on KALY's patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations. KALY management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.
Updated KALY Analyst Report Planned For Publication Next Week
In addition to the corporate financial disclosures released earlier today, KALY's alternative reporting site, www.kaly-info.com, includes an analyst report on KALY's overall business operation in addition to other useful information. In conjunction with the recent cannabis extract biopharmaceutical business updates made this week, KALY anticipates publishing an updated analyst report next week.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
https://ml.globenewswire.com/media/377690e7-27c3-4fa3-a20c-d1cc6216cc70/small /kaly-logo-new-march-21-png.png
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
Richard Gouldings credibility is shot. He looked like one scared worried crook when he was on the Diamond CBD's website as CEO. Now I see why with the Vacarro lawsuit. Is Goulding, than Hagen Next? Whats the dump about today?
That's why I said I heard. Which I did on this board. I don't have e trade.
800,000 buys, 100,000 sells
The walls are down, the mm's will let this rise, slap the ask.
I heard E trade stopped offering POTN to trade. If true, that is a massive red flag.
LiveWire Ergogenics, Inc Reports Second Quarter 2019 Financial Results
Today 9:30 AM ET (GlobeNewswire)Print
LiveWire Ergogenics, Inc. (OTC: LVVV) announced today that it is has recently filed its Second Quarter 2019 Financial Report with OTC Markets.
LiveWire Ergogenics, through its subsidiary GHC Ventures, generated $371,876 in revenue, a significant improvement over the same period last year. The increase in revenue of over 2000% is a result of State licensed Distribution and Nursery operations in California. General and Administrative costs increased slightly to $176,571, due to the additional personnel to manage GHC operations. At the same time, the Company has been able to reduce its stock-based compensation significantly and did not issue any new shares during the second quarter of 2019, keeping down dilution for our existing shareholders.
Bill Hodson, CEO of LiveWire stated, "To continue this path of aggressively increasing revenues, we have substantially expanded the operation of our subsidiary, GHC Ventures, and have implemented an all-encompassing software tracking system to capture all transactions. The system allows us to track and trace every transaction and comply with California State and tax authorities' rules and regulations that come along with this growing industry. Below you will find a summary of all milestone achievements within our group of companies for the last few months that we believe will have a positive impact in the months ahead."
-- Finalized acquisition of a 265-acre Ranch in Paso Robles, California via our subsidiary to establish the world's first Estate Grown Weedery.
-- Received cultivation/nursery and distribution permits for nursery in Coachella, California.
-- Received cultivation/nursery Minor Use Permit for its nursery in Paso Robles, California.
-- Received Annual CA State distribution license from the California Bureau of Cannabis Control.
-- Began operation of statewide distribution division GHC Ventures for distribution of cannabis products throughout California.
-- Applied for Minor Use Permit for outdoor cultivation on Estrella Ranch.
-- Commenced the vetting process and begun negotiations with several potential third-party operators for Estrella Ranch.
-- Executed "7X Pure" Private Label Agreement with botanical company with first product release imminent.
-- Engaged research teams with highly recognized athletes and published experts to commence with leading-edge research to explore the application of cannabinoid products for human and equine applications.
-- Advancing plans for expansion into the sports and cosmetics markets for CBD or THC infused products.
-- Continuing to explore potential acquisition targets and strategic alliances.
-- Continued preparation for up-listing to OTCQB through financial audits and OTC filings.
We will keep you updated, and we appreciate your trust and loyalty.
In the meanwhile, enjoy the video of our Paso Robles Estate Grown Weedery.
Click here to view Estrella Ranch video
About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) specializes in identifying and monetizing current and future trends in the human and veterinarian health and wellness industry. The Company is focused on acquiring, managing and licensing specialized "closed loop" turnkey cannabis real estate locations of fully compliant and permitted turnkey facilities to produce cannabis-based products and services in California and the state-wide distribution of these products. This includes verification of zero pesticide products for quality brands via its "7X Pure" Cannabis Verification System, and the development, licensing and distribution of legal, high-quality cannabinoid-based products and services. LiveWire Ergogenics does not sell or distribute products that are in violation of the Unites States Controlled Substance Act.
POTN needs to clear up some issues before I get back on board. Even .03 is risky with POTN.
Smack the ask, get this run started already! Solid opportunity to make dough. This stock will run unless the bid sitters hold it down.
IGPK is Way oversold. Yield sign is overrated 80% of the time.
Looking good today 4 sure!
LiveWire Ergogenics, Inc Reports Significant Revenue Improvement for Second Quarter 2019
Posted by SWI Editorial Staff On August 21, 2019 0 Comment
Anaheim, CA – August 22, 2019 – LiveWire Ergogenics, Inc. (OTC: LVVV) announced today that it is has filed its Second Quarter 2019 Financial Report with OTC Markets, showing significant improvement in revenue for the quarter.
LiveWire Ergogenics, through its subsidiary GHC Ventures, generated $371,876 in revenue, a significant improvement over the same period last year. The increase in revenue of over 2000% is a result of State licensed Distribution and Nursery operations in California. General and Administrative costs increased slightly to $176,571, due to the additional personnel to manage GHC operations. At the same time, the Company has been able to reduce its stock-based compensation significantly and did not issue any new shares during the second quarter of 2019, keeping down dilution for our existing shareholders.
Bill Hodson, CEO of LiveWire stated, “To continue this path of aggressively increasing revenues, we have substantially expanded the operation of our subsidiary, GHC Ventures, and have implemented an all-encompassing software tracking system to capture all transactions. The system allows us to track and trace every transaction and comply with California State and tax authorities’ rules and regulations that come along with this growing industry. Below you will find a summary of all milestone achievements within our group of companies for the last few months that we believe will have a positive impact in the months ahead.”
- Finalized acquisition of a 265-acre Ranch in Paso Robles, California via our subsidiary to establish the world’s first Estate Grown Weedery.
- Received cultivation/nursery and distribution permits for nursery in Coachella, California.
- Received cultivation/nursery Minor Use Permit for its nursery in Paso Robles, California.
- Received Annual CA State distribution license from the California Bureau of Cannabis Control.
- Began operation of statewide distribution division GHC Ventures for distribution of cannabis products throughout California.
- Applied for Minor Use Permit for outdoor cultivation on Estrella Ranch.
- Commenced the vetting process and begun negotiations with several potential third-party operators for Estrella Ranch.
- Executed “7X Pure” Private Label Agreement with botanical company with first product release imminent.
- Engaged research teams with highly recognized athletes and published experts to commence with leading-edge research to explore the application of cannabinoid products for human and equine applications.
- Advancing plans for expansion into the sports and cosmetics markets for CBD or THC infused products.
- Continuing to explore potential acquisition targets and strategic alliances.
- Continued preparation for up-listing to OTCQB through financial audits and OTC filings.
We will keep you updated, and we appreciate your trust and loyalty.
This is going to break out IMO.
Why did IGPK drop so hard? I grabbed some the other day. up 30%. I think IGPK realistically and honestly has a good chance to at least double your money relatively quick. I could be wrong. But I been seeing a lot of penny stocks lately that dropped to below 52 week lows and have shot up huge in the last week. I like IGPK. TGGI looks like it is about to hit ones on the ask. Starting to wonder if TGGI might have finally died after all these years.
One thing I never liked was the expression on the CEo's face on Diamond CBD's website. He looked so worried in such an important pic on the website. I think it is no longer on there. I wondered... What is he so worried looking for? I am worried more charges are coming later possibly in the CV case. Massive Blowout sale on the website! they never used BLOWOUT sale before to promote. Sounds desperate to me. .03 sounds about right after those weaker than expected numbers.
Lets get this party started! LVVV's 7x pure cannabis production system will be a huge winner. Cali Buds are the best in the world.
You noticed its gonna run to I see. Lets do this people! SMACK DA ASK! Lets get paid!
I sold today. POTN is a shady stock for sure. 25 million in revs and only 250,000 profit says it all. CBD is a fad that will die. THC is what people want.
Is LVVV a winner? Cali pot is superior to Canadian IMO because Cali sun is Magic for Cannabis plants. LVVV seems to be trying to create the Cannabis veteran smokers are searching for. That LVVV 7x purity system is Whats up.
All Selling no buying today. 100 mil DUMP!!! https://ih.advfn.com/stock-market/USOTC/trans-global-group-inc-pc-TGGI/trades
Bank Of America Downgrades Aurora Cannabis, Concerned About Cash Burn
Today 11:06 AM ET (Benzinga)Print
Aurora Cannabis Inc (NYSE: ACB) deserves credit for building industry leading scale and strong margins, but Bank of America thinks the company is burning fast at a concerning pace.
The Analyst
Bank of America's Christopher Carey downgraded Aurora's U.S.-listed stock from Buy to Neutral with a price target lowered from $10 to $8.
The Thesis
Aurora could be considered "among the best" cannabis companies and similar to its peers, Aurora is bleeding out cash, Carey wrote in the note. Aurora's cash position is "less robust" compared to its peers and is on track to turn negative as early as the first quarter 2020.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!
Aurora faces a large convertible debenture of CA$230 million at a price of CA$13.05 (versus CA$9.68 at the time of the analyst's note), which is "well out of the money" and may need to be settled in cash. Aurora's cash burn stems from its investments in four production facilities that consists of around 1.35 million new square feet of facility space across Canada, Denmark and Portugal. Based on current estimates, Aurora will have a "paltry" CA$70 million of cash on hand in the first quarter, but the out-of-money convert would bring the cash position in the red.
Ultimately, Aurora's premier status in the cannabis space should help it secure any necessary financing gaps, which implies concerns of solvency are unjustified. It's "less ideal" to seek out new capital from a defensive position compared to other companies who raise capital for "larger untapped growth opportunities," including U.S. CBD-focused companies.
Price Action
Shares of Aurora Cannabis were trading lower by more than 6.6% at $6.92 Thursday morning.
Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.
Latest Ratings for ACB DateFirmActionFromTo
Jul 2019DowngradesBuyNeutral Jul 2019Initiates Coverage OnBuy Jun 2019Initiates Coverage OnHold
View More Analyst Ratings for ACB
View the Latest Analyst Ratings
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.